Late cognitive and adaptive outcomes of patients with neuroblastoma‐associated opsoclonus‐myoclonus‐ataxia‐syndrome: A report from the Children's Oncology Group
Prerna Kumar,
Victoria W. Willard,
Leanne Embry
et al.
Abstract:BackgroundOpsoclonus‐myoclonus‐ataxia syndrome (OMAS) is a rare autoimmune disorder of the nervous system presenting with abnormal eye and limb movements, altered gait, and increased irritability. Two to four percent of children diagnosed with neuroblastoma have neuroblastoma‐associated OMAS (NA‐OMAS). These children typically present with non‐high‐risk neuroblastoma that is cured with surgery, with or without chemotherapy. Despite excellent overall survival, patients with NA‐OMAS can have significant persiste… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.